AHR and central nervous system cancer: Drugs that can block cancer cell invasion are urgently sought after, and we discovered that ITE, an endogenous ligand of AHR, could block migration of the glioma cells ex vivo and in vivo, supporting ITE to be investigated as a lead compound.